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Stress toleranceOur previous studies demonstrated that RSK2 plays a key role in cell proliferation and transformation
induced by tumor promoters such as epidermal growth factor (EGF) in mouse and human skin cells. How-
ever, no direct evidence has been found regarding the relationship of RSK2 and cell survival. In this study,
we found that RSK2 interacted and phosphorylated GSK3b at Ser9. Notably, GSK3b phosphorylation at
Ser9 was suppressed in RSK2/ MEFs compared with RSK2+/+ MEFs by stimulation of EGF and calcium
ionophore A23187, a cellular calcium stressor. In proliferation, we found that RSK2 deﬁciency suppressed
cell proliferation compared with RSK2+/+ MEFs. In contrast, GSK3b/ MEFs induced the cell proliferation
compared with GSK3b+/+ MEFs. Importantly, RSK2/ MEFs were induced severe cellular morphology
change by A23187 and enhanced G1/G0 and sub-G1 accumulation of the cell cycle phase compared with
RSK2+/+ MEFs. The sub-G1 induction in RSK2/ MEFs by A23187 was correlated with increase of cyto-
chrome c release, caspase-3 cleavage and apoptotic DNA fragmentation compared with RSK2+/+ MEFs.
Notably, return back of RSK2 into RSK2/ MEFs restored A23187-induced morphological change, and
decreased apoptosis, apoptotic DNA fragmentation and caspase-3 induction compared with RSK2//
mock MEFs. Taken together, our results demonstrated that RSK2 plays an important role in stress-toler-
ance and cell survival, resulting in cell proliferation and cancer development.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license.1. Introduction
The p90-kDa ribosomal S6 kinases (p90RSKs) are a family of ser-
ine/threonine kinases including RSK1, RSK2, RSK3, RSK4, MSK1 and
MSK2 [1], and regulated their activities responding to many
growth factors, peptide hormones, neurotransmitters [2,3] and
environmental stresses such as ultraviolet (UV) light [4] through
the mitogen-activated protein (MAP) kinases, key regulators of cell
proliferation and oncogenesis [5,6]. Activated RSK2 is translocated
to the nucleus and phosphorylates diverse nuclear proteins, includ-
ing c-Fos, ELK-1, histones, cyclic AMP responsive element binding
protein (CREB) protein [7–11], activating transcription factor 4
(ATF4) [12], p53 [13], NFAT3 [14] and ATF1 [15]. Because RSK2 en-
zyme has broad substrate spectrum, it might be able to interact
with diverse substrates that regulates cell proliferation, differenti-
ation, transformation and stress resistance, depending on the spe-
ciﬁc context.GSK3 that is present in mammals in two isoforms, a and b, is an
ubiquitous serine/threonine kinase [16] and identiﬁed as an en-
zyme to phosphorylate glycogen synthase, resulting in inhibition
of glycogen synthesis [17]. The general regulatory mechanism is
the phosphorylation of GSK3b at Ser9 or GSK3a at Ser21, which
inhibits activity, by through phosphatidylinositol 3-kinase (PI3K)/
AKT signaling pathway [18]. In contrast, GSK3 enzyme activity is
induced by intramolecular autophosphorylation of Tyr216 in
GSK3b and Tyr279 in GSK3a, resulting in enhancement of the sta-
bility of the enzymes [19]. Because dysregulation of GSK3 activity
is associated with variety of human diseases such as mood disor-
der, neurodegenerative disease, cancer, inﬂammatory reaction
and cardiovascular disease and cellular apoptosis, GSK3 must be
tightly regulated [20].
The intrinsic apoptosis signaling pathway can be induced by
numerous stimuli, which cause cell damage including DNA dam-
age, oxidative stress and endoplasmic reticulum (ER) stress. The
intrinsic apoptosis cascade causes the destruction of mitochondria
mediated by enhancement of GSK3 activity [20]. When cells are
stimulated with apoptotic stimuli such as DNA damage or ER
stress, GSK3b activity is increased in mitochondria [21,22]. More-
over, the activation of GSK3b in nucleus induces p53-dependent
expression of Bax in response DNA damage [23,24] and inhibits
CREB, which blocks the CREB-mediated expression of the
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cations indicated that RSK2 phosphorylates and inactivates proa-
poptotic protein BAD, resulting in induction of cell survival [26],
and RSK2 up-regulates the transcription of anti-apoptotic Bcl-2
through CREB phosphorylation and activation [27]. On account of
apoptosis is presumed to have a protective function against carci-
nogenesis and cell survival, these effects suggest that the function
of RSK2 might have correlation in enhancing tumorigenesis and
cell survival. These possibilities have been provided by our re-
searches that RSK2 phosphorylates and activates various transcrip-
tion factors and epigenetic factors involved in cell proliferation and
transformation [12–15]. However, molecular mechanisms on the
RSK2-mediated cell survival have not been clearly understood.
In this study, we found that GSK3b was a binding partner and a
substrate of RSK2. RSK2 phosphorylated GSK3b at Ser9, resulted in
the enhancing of cell survival by the induction of calcium stress
tolerance.2. Materials and methods
2.1. Reagents and antibodies
Chemical reagents, including Tris, NaCl, and SDS for molecular
biology and buffer preparation were purchased from Sigma–Al-
drich (St. Louis, MO, USA). Cell culture medium and other
supplements were purchased from Life Science Technologies,
Inc. (Rockville, MD, USA). Antibodies for Western blot
analysis were purchased from Cell Signaling Technology, Inc.
(Beverly, MA, USA), Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA), or Millipore Korea Co., Ltd, (Gangnam-gu, Seoul,
Korea).2.2. Cell culture and transfection
293T, GSK3b+/+ and GSK3b/, and RSK2+/+ and RSK2/ mouse
embryonic ﬁbroblasts (MEFs) were cultured with Dulbecco’s mod-
iﬁed Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and antibiotics at 37 C in a 5% CO2 incubator. The cells
were split at 90% conﬂuent and medium was changed every other
day. To stimulate calcium in RSK2+/+ and RSK2/ MEFs, the cells
(1  106) was seeded, cultured for overnight at 37 C in a 5% CO2
incubator, starved for 16–24 h and then treated indicated dose of
A23187.2.3. Mammalian two-hybrid assay
293T cells (2.0  104) were seeded into 48-well plates and incu-
bated with 10% FBS-DMEM for 18 h before transfection. The DNAs,
pACT-GSK3b, pBIND-kinases and pG5-luciferease, were combined
in the same molar ratio and the total amount of DNA was not more
than 100 ng per well. The transfection was performed using jetPEI
following the manufacturer’s recommended protocols. The cells
were disrupted by addition of cell lysis buffer directly into each
well of the 48-well plate and then aliquots of 20 ll were added
to each well of a 96-well luminescence plate. The luciferase activity
was measured automatically by computer program (PerkinElmer,
Waltham, MA, USA). The relative luciferase activity was calculated
and normalized based on the pG5-luciferase basal control. For
assessment of transfection efﬁciency and protein amount, the
luciferase assay, renilla luciferase activity assay or Lowry protein
assay were used.2.4. MTS assay
To estimate proliferation, GSK3b+/+, GSK3b/, RSK2+/+ and
RSK2/MEFs (1  103 cells/well) were seeded into 96-well plates.
After culturing for 2 h, 20 ll of the CellTiter 96 Aqueous One Solu-
tion (Promega, Madison, WI) were added to each well and cells
were then incubated for 1 h at 37 C and 5% CO2. To stop the reac-
tion, 25 ll of a 10% SDS solution were added and absorbance was
measured at 492 and 690 nm using xMark microplate spectropho-
tometer (Bio-RAD, Philadelphia, PA, USA). The MTS assay was con-
ducted at 24 h intervals for 96 h.
2.5. Western blotting
Samples containing equal amounts of protein were resolved by
the appropriate percentage SDS-PAGE and then transferred onto
PVDF (polyvinylidene diﬂuoride) membranes. The membranes
were incubated in blocking buffer and then probed with speciﬁc
primary antibodies against appropriate target proteins. The Wes-
tern blots were visualized using an enhanced chemiluminescence
detection system (ECL, Amersham Biosciences Corp., Piscataway,
NJ. USA).
2.6. In vitro kinase assay
A GST-GSK3b protein was used as a substrate for an in vitro ki-
nase assay with active RSK2 (Millipore Korea Co., Ltd, Gangnam-gu,
Seoul, Korea)). Reactions were carried out at 30 C for 30 min in a
mixture containing 50 lM unlabeled ATP and 10 lCi [c-32P] ATP,
and then were stopped by adding 6 SDS sample buffer. 32p-la-
beled GSK3b was visualized by autoradiography. The input was
conﬁrmed using an identical experimental set by Western blotting
using speciﬁc antibodies as indicated. To examine the phosphory-
lation site conformation of GSK3b by RSK2, GST-GSK3b and active
RSK2 were mixed with cold ATP alone and conducted at 30 C for
30 min. The GSK3b phosphorylation at Ser9 by active RSK2 was
visualized Western blotting using speciﬁc primary and HRP-conju-
gated secondary antibodies as indicated.
2.7. Cell cycle and apoptosis analysis
RSK2+/+ or RSK2/ cells (2  105) were seeded into 60-mm
dishes and cultured for 16 h at 37 C in a 5% CO2 incubator. The cell
was starved 24 h with 0.1% FBS-DMEM and then stimulated with
indicated dose of A23187 for 12 h. For the cell cycle analysis, the
cells were trypsinized, ﬁxed with methanol, stained with propidi-
um iodide (PI; Sigma–Aldrich, St. Louis, MO, USA). For the apopto-
sis analysis, the cells were harvested, washed with cold PBS and
the directly stained with PI and annexin V (Life Science Technolo-
gies, Inc, Rockville, MD, USA). The cells were analyzed for cell cycle
phase, sub-G1 populations or apoptosis using FACS Calibur ﬂow
cytometer (BD Bioscience, San Jose, CA, USA) as described by Ah-
mad et al. [28].
2.8. DNA fragmentation assay
RSK2+/+ and RSK2/ MEFs, the cells (1  106) was seeded and
cultured to 90% conﬂuent at 37 C in a 5% CO2 incubator. The cells
were stimulated with indicated dose of A23187 for 24 h and har-
vested. The cells were suspended with 500 ll of cell lysis buffer
[10 mM Tris–HCl (pH 8.0), 100 mM EDTA (pH 8.0), 0.5% SDS] and
treated with 100 lg/ml of proteinase K at 55 C for 4 h. The total
genomic DNA was isolated by phenol/chloroform extraction and
ethanol precipitation, and RNA was eliminated by adding RNase
A. Total 5 lg of genomic DNA was electrophoresed onto 1.2%
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bromide staining and photographed.3. Results and discussion
3.1. RSK2 deﬁciency enhances A23187-induced apoptosis
Activated RSK2-mediated pro-apoptotic BAD phosphorylation
at serine 112 inactivates BAD and induces cell survival [26]. Our
previous results demonstrated that UVB stimulation induces sub-
G1 accumulation in RSK2/ MEFs compared with RSK2+/+ MEFs
[4]. A recent report indicated that UV-induced apoptosis signaling
was also enhanced by intracellular calcium inﬂux [29], Based onFig. 1. RSK2 deﬁciency enhances A23187-induced apoptosis. (A–B) RSK2 deﬁciency indu
were analyzed cell cycle distribution and Sub-G1 by treatment of A23187 as described
cytochrome c release and caspase-3 cleavage by A23187. (D) RSK2 deﬁciency enhances D
A23187 and DNA fragmentation was visualized as described in ‘‘Materials and methods’’
treated with A23187 and analyzed apoptosis by PI/annecxin V staining using FACS Calibthese results, we hypothesized that RSK2 might a survival factor
when cells are stimulated with A23187. To examine the hypothe-
sis, we stimulated RSK2+/+ or RSK2/ MEFs with A23187. We
found that attached RSK2/MEFs in culture vessels were dramat-
ically increased the G1 cell cycle phase and decreased S cell cycle
phase compared with attached RSK2+/+ MEFs by A23187 in dose
dependent manner (Fig. 1A). RSK2 deﬁciency induced morpholog-
ical changes with cytoplasmic shrinkage, fragmentation and
detachment (Supplementary Fig. 1A). Notably, RSK2 deﬁciency in-
creased sub-G1 cell cycle phase to about 75% in the total cell pop-
ulation compared with about 20% of sub-G1 cell cycle phase in
RSK2+/+ MEFs (Fig. 1B and Supplementary Fig. 1B). Importantly,
we found that RSK2/ MEFs showed dramatic induction of cyto-
solic cytochrome c and reduction of membrane cytochrome c byces accumulation of G1/G0 cell cycle phase by A23187. RSK2+/+ and RSK2/ MEFs
in ‘‘Materials and methods’’ (⁄p < 0.01 and ⁄⁄p < 0.001). (C) RSK2/ MEFs enhance
NA fragmentation induced by A23187. RSK2+/+ and RSK2/MEFs were treated with
. (E) RSK2 deﬁciency induces apoptosis by A23187. RSK2+/+ and RSK2/ MEFs were
ur ﬂow cytometer.
Fig. 2. GSK3b is a binding partner and substrate of RSK2. (A) Identiﬁcation of protein–protein interaction in ex vivo by mammalian two-hybrid assay. The pBIND-AKT2 and -
AKT3 were used as positive controls (⁄p < 0.05; ⁄⁄p < 0.005). (B) Immunoprecipitation of RSK2 with GSK3b. The expression vectors were transfected into 293 cells as indicated
and protein binding was analyzed by co-immunoprecipitation (IP) and Western blotting using HA and His antibodies as indicated. (C) In vitro kinase. Active RSK2 and GSK3b
puriﬁed from Sf1 insect cells were combined with 10 lCi of [c-32p] ATP and in vitro kinase assay was conducted as described in ‘‘Materials and methods’’. (D) Cell proliferation
analysis of GSK3b+/+, GSK3b/, RSK2+/+ and RSK2/ MEFs. The GSK3b+/+, GSK3b/, RSK2+/+ or RSK2/ MEFs (1  103) were seeded into 96-well culture plates and cell
proliferation was measured for 96 h in 24 h intervals by MTS assay (⁄p < 0.05; ⁄⁄p < 0.005).
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release into cytosol by A23187 induced cleavage of caspase-3, a
critical modulating factor inducing cell apoptosis, and reduced pro-
caspase-3 in RSK2/ MEFs (Fig. 1C). In contrast, RSK2+/+ MEFs
showed marginal reduction of procaspase-3 by A23187 (Fig. 1C),
indicated that RSK2 might inhibit upstream caspases of caspase-
3 or activate calcium pumps from cytosol toward ER inside or out-
side of cells. As expected, we observed extensive DNA fragmenta-
tion in RSK2/ MEFs by A23187 treatment compared with
RSK2+/+ MEFs (Fig. 1D). Moreover, the quantiﬁcation analysis of
apoptotic cell population demonstrated that RSK2/ MEFs were
signiﬁcantly increased the apoptosis by A23187 compared with
RSK2+/+ MEFs (Fig. 1E). Taken together, RSK2 plays an important
role in stress-tolerance and cell survival induced by calcium stress.
3.2. GSK3b is a binding partner and substrate of RSK2
MAP kinase including ERKs, p38 kinases and JNKs, and AKT/
GSK3b signaling pathways are activated by diverse extracellular
stimulations in a short time including growth factors, cytokines
and environmental stresses such as UVB stimulation, and regulatecell proliferation, transformation and stress resistance, depending
on the speciﬁc context [14,30]. To examine the signaling pathway
to involve the GSK3b-mediated stress tolerance induced by cal-
cium, we conducted mammalian two-hybrid assay to identify the
novel binding partners of GSK3b. We found that GSK3b interacted
strongly with RSK2 (Fig. 2A). GSK3b and RSK2 binding was stronger
than that of GSK3b and AKT3 (Fig. 2A), which is a well-known up-
stream kinase of GSK3b at Ser9 when cells are stimulated with
growth factors such as insulin [31]. To conﬁrm whether GSK3b
and RSK2 were interact each other or not, we ectopically expressed
RSK2 and GSK3b in 293T cells and then veriﬁed GSK3b and RSK2
interaction by immunoprecipitation. We found that GSK3b inter-
acted with RSK2 (Fig. 2B). Although previous publications indi-
cated that RSK was an upstream kinase of GSK3b [32], no direct
evidence has been provided in vitro. To examine this hypothesis,
we conducted in vitro kinase assay using puriﬁed GST-GSK3b and
active RSK2, which are commercially available, and [c-32p]ATP
radioisotope, and found that GSK3b was phosphorylated by RSK2
(Fig. 2C). Notably, we conﬁrmed that the proliferation of GSK3b/
 and RSK2+/+ MEFs was faster than those of GSK3b+/+ and RSK2/
, respectively (Fig. 2D, left and right graphs). Taken together, these
Fig. 3. GSK3b Ser9 is a target phosphorylation amino acid by RSK2. (A) Putative phospho-amino acid(s) of GSK3b that could be phosphorylated by RSK were identiﬁed using
the Group-based Prediction System (v2.1). (B) RSK2 phosphorylates GSK3b at Ser9. In vitro kinase assay using the GSK3b protein and active RSK2 was conducted as described
in ‘‘Materials and methods’’. (C) RSK2 deﬁciency attenuates EGF-induced GSK3b phosphorylation at Ser9. Indicated protein levels were analyzed by Western blotting by
stimulation of EGF in RSK2+/+ and RSK2/ MEFs. (D) The phosphorylation of GSK3b at Ser9 was compared by EGF or A23187 stimulation in RSK2+/+ MEFs as indicated.
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RSK2/GSK3b signaling axis might play an important role in cell
proliferation.
3.3. GSK3b Ser9 is a target phosphorylation amino acid by RSK2
Previous our report demonstrates that RSK2-mediated phos-
phorylation consensus amino acid sequences is RxRxxS/T [33]. To
search whether GSK3b contained RSK2 target amino acid or not,
we downloaded human GSK3b amino acid from human protein ref-
erence databases (http://www.hprd.org) and surveyed RSK2 target
amino acid consensus sequences. We found that GSK3b Ser9 con-
tained RxRxxS/T RSK2-mediated phosphorylation target consensus
sequences (Supplementary Fig. 2A). None of other known
phosphorylation sites of GSK3b were matched with RSK2 target
consensus amino acid motif (Supplementary Fig. 2A). To verifywhether GSK3b Ser9 was a putative RSK2 target or not, we
searched kinase-speciﬁc phosphorylation sites using Group-based
prediction system (GPS v2.1) [34]. We found that GSK3b Ser9
showed the highest score/cutoff values about 4.97 among pre-
dicted phosphorylation sites by RSK family members (Fig. 3A). Fur-
thermore, RSK showed the highest score/cutoff values about
among the predicted putative kinases to phosphorylate GSK3b at
Ser9 compared with about 3.13 of the AKT2, which is a well-known
GSK3b (Supplementary Fig. 2B). To conﬁrm the phosphorylation
amino acid of GSK3b by RSK2, we conducted in vitro kinase assay
with active RSK2 and GST-GSK3b, and conﬁrmed the phosphoryla-
tion of GSK3b at Ser9 by Western blotting. Notably, phosphoryla-
tion of GSK3b at Ser9 was increased by RSK2 in a dose
dependent manner (Fig. 3B), indicated that RSK2 is a GSK3b kinase.
We further conﬁrmed that EGF-induced GSK3b phosphorylation at
Ser9 in RSK2+/+ MEFs was suppressed in RSK2/ MEFs (Fig. 3C).
Fig. 4. Adding back RSK2 to RSK2/MEFs restores stress tolerance. (A) A23187-induced phospho-signaling protein proﬁles. RSK2+/+ MEFs were stimulated with A23187 and
then indicated protein levels were analyzed by Western blotting. (B) RSK2 deﬁciency attenuates A23187-induced GSK3b phosphorylation at Ser9. The GSK3b phosphorylation
at Ser9 induced by A23187 treatment was compared in RSK2+/+ and RSK2/ MEFs by combination of A23187 and LY294005 as indicated. (C) RSK2 reintroduction into
RSK2/MEFs induces GSK3b phosphorylation at Ser9 and reduces caspase-3 cleavage by A23187 treatment. (D) Re-introduction of RSK2 into RSK2/MEFs restores A23187-
induced DNA fragmentation. (E) Adding back RSK2 to RSK2/ MEFs suppresses A23187-induced apoptosis.
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tally disappeared in RSK2/ MEFs (Fig. 3C), indicated that EGF-in-
duced AKT might involve in GSK3b phosphorylation at Ser9. In
addition, we found that GSK3b phosphorylation at Ser9 was simi-
larly induced by EGF or A23187 treatment and total protein levels
of GSK3b were suppressed by EGF or A23187 treatment (Fig. 3D).
These results demonstrated that GSK3b was a direct substrate of
the RSK2 and phosphorylated by RSK2 at Ser9.
3.4. Adding back RSK2 to RSK2/ MEFs restores stress tolerance
Our previous studies indicate that RSK2 inhibits BAD activity
[26] and enhances Bcl-2 gene expression [27]. Because apoptosis
have a protective function against carcinogenesis, we examined
and conﬁrmed that sub-G1 population was increased in RSK2/
MEFs compared with RSK2+/+ MEFs when the cells were exposured
with UVB (4 kJ/m2) [4]. A recent report indicated that UV-induced
apoptosis signaling was also enhanced by intracellular calcium in-
ﬂux [29]. Furthermore, our results demonstrated that RSK2/
MEFs induced apoptosis by A23187 treatment (Fig. 1). Thus, we
examined the A23187-induced phosphorylation protein proﬁles
in RSK2+/+ MEFs and found that GSK3b phosphorylation at Ser9
was followed by the phosphorylation of RSK2 at Ser227 (Fig. 4A).
Importantly, the phosphorylation of AKT at Ser308 and Thr473
was showed later than GSK3b phosphorylation at Ser9 (Fig. 4A).
Moreover, GSK3b phosphorylation at Ser9 induced by A23187 didnot suppressed by co-treatment of A23187 and LY294002, a spe-
ciﬁc inhibitor of PI3K, in RSK2+/+ MEFs (Fig. 4B). These results dem-
onstrated that GSK3b Ser9 phosphorylation signaling induced by
A23187 is mediated through ERKs/RSK2 signaling pathway, not
through the PI3K/AKT signaling pathway. Notably, RSK2/ MEFs
showed different phosphorylation patterns of GSK3b at Ser9 com-
pared with RSK2+/+ MEFs by A23187, LY294002 or A23187/
LY294002 treatment (Fig. 4B), indicated that other signaling path-
way to phosphorylate GSK3b at Ser9 might exist except RSK2 and
AKT. Additionally, inhibitory effect of LY294002 on the PI3K was
conﬁrmed by inhibition of AKT phosphorylation at Ser308 by co-
treatment with A23187 and LY294002 (Fig. 4B). We further con-
ﬁrmed that adding back of RSK2 into RSK2/ MEFs (RSK2//
RSK2) [15] showed the increase of GSK3b phosphorylation at
Ser9 (Fig. 4C). In contrast with GSK3b phosphorylation, cleaved
caspase-3 content was suppressed in RSK2//RSK2 MEFs com-
pared with RSK2//mock MEFs (Fig. 4C). Notably, the increased
DNA fragmentation induced by A23187 in RSK2//mock MEFs
was suppressed in RSK2//RSK2 MEFs compared with RSK2//
mock MEFs (Fig. 4D). Notably, the apoptotic population was signif-
icantly reduced in RSK2//RSK2 MEFs compared with RSK2//
mock MEFs by A23187 treatment (Fig. 4E). These results suggested
that RSK2 might play an important role in stress tolerance and cell
survival.
Our previous results demonstrated that RSK2-mediated BAD
phosphorylation suppressed apoptosis, resulting in the increase
118 C.-J. Lee et al. / Biochemical and Biophysical Research Communications 440 (2013) 112–118of cell survival [26]. Moreover, we have demonstrated that RSK2
plays an important role in cell proliferation, transformation and
cancer development in human [4,35,36]. Generally, cells trans-
formed to cancer cells gains resistance from the cell death induced
by environmental stresses and chemotherapeutic compounds [37].
Although molecular mechanisms are necessary to elucidate RSK2/
GSK3b signaling pathway in stress tolerance and cell survival in fu-
ture, our study demonstrates that a regulation mechanism of
RSK2-mediated GSK3b activity might give a context to enhance cell
survival, resulting in acquirement of abilities to increase cell prolif-
eration and anti-therapeutic resistance in human cancer.
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